Tricida Inc (TCDA) Insider Geoffrey M. Parker Purchases 5,000 Shares of Stock
Tricida Inc (NASDAQ:TCDA) insider Geoffrey M. Parker bought 5,000 shares of the business’s stock in a transaction on Tuesday, November 13th. The shares were purchased at an average cost of $29.72 per share, with a total value of $148,600.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website.
Tricida stock opened at $29.29 on Wednesday. Tricida Inc has a fifty-two week low of $21.87 and a fifty-two week high of $40.10.
Tricida (NASDAQ:TCDA) last released its earnings results on Thursday, November 8th. The company reported ($0.65) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.84) by $0.19. Equities analysts forecast that Tricida Inc will post -3.12 earnings per share for the current fiscal year.
A number of research firms have weighed in on TCDA. Cowen reissued a “buy” rating on shares of Tricida in a research report on Friday, November 9th. Zacks Investment Research raised shares of Tricida from a “hold” rating to a “buy” rating and set a $41.00 target price for the company in a research report on Tuesday, September 25th. JPMorgan Chase & Co. began coverage on shares of Tricida in a research report on Monday, July 23rd. They set a “neutral” rating and a $34.00 target price for the company. Finally, Goldman Sachs Group began coverage on shares of Tricida in a research report on Monday, July 23rd. They set a “neutral” rating and a $32.00 target price for the company.
COPYRIGHT VIOLATION WARNING: “Tricida Inc (TCDA) Insider Geoffrey M. Parker Purchases 5,000 Shares of Stock” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.thecerbatgem.com/2018/11/14/tricida-inc-tcda-insider-geoffrey-m-parker-purchases-5000-shares-of-stock.html.
Tricida, Inc, a late-stage pharmaceutical company, focuses on developing therapeutics to address renal, metabolic, and cardiovascular disease. Its lead product candidate, TRC101, a non-absorbed orally-administered polymer drug that is in Phase III clinical trials used to treat metabolic acidosis in patients with chronic kidney disease.
Further Reading: What is a Swap?
Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.